Compare PTCT & ALK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTCT | ALK |
|---|---|---|
| Founded | 1998 | 1932 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Air Freight/Delivery Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.4B |
| IPO Year | 2006 | 2003 |
| Metric | PTCT | ALK |
|---|---|---|
| Price | $69.14 | $37.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 13 |
| Target Price | ★ $80.65 | $63.69 |
| AVG Volume (30 Days) | 915.0K | ★ 4.8M |
| Earning Date | 05-05-2026 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 264.48 | N/A |
| EPS | ★ 7.78 | 0.83 |
| Revenue | $264,734,000.00 | ★ $10,426,000,000.00 |
| Revenue This Year | N/A | $10.54 |
| Revenue Next Year | $19.30 | $5.44 |
| P/E Ratio | ★ $8.71 | $44.98 |
| Revenue Growth | ★ 36.19 | 8.09 |
| 52 Week Low | $35.95 | $33.03 |
| 52 Week High | $87.50 | $65.35 |
| Indicator | PTCT | ALK |
|---|---|---|
| Relative Strength Index (RSI) | 55.26 | 40.72 |
| Support Level | $64.00 | $37.16 |
| Resistance Level | $69.23 | $40.62 |
| Average True Range (ATR) | 2.24 | 1.95 |
| MACD | 0.57 | 0.43 |
| Stochastic Oscillator | 81.53 | 58.96 |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
Alaska Air Group Inc operates two airlines, Alaska and Horizon, in three operating segments. The Alaska Airlines segment includes scheduled air transportation on Alaska's Boeing and Airbus jet aircraft for passengers and cargo throughout the U.S., and in parts of Mexico and Costa Rica. The Regional segment includes Horizon's and other third-party carriers' scheduled air transportation for passengers across a shorter distance network within the U.S. and Canada under capacity purchase agreements. The Hawaiian Airlines segment includes scheduled air transportation on Hawaiian's Boeing and Airbus aircraft for passengers and cargo. It earns revenues from Passenger tickets, including ticket breakage and net of taxes and fees, Passenger ancillary, and Mileage Plan passenger revenue.